Brukinsa and Nasopharyngitis - a phase IV clinical study of FDA data

Summary:

Nasopharyngitis is reported as a side effect among people who take Brukinsa (zanubrutinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Imbruvica, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Nasopharyngitis when taking Brukinsa. It is created by eHealthMe based on reports of 1,330 people who have side effects when taking Brukinsa from the FDA, and is updated regularly.

What is Brukinsa?

Brukinsa has active ingredients of zanubrutinib. eHealthMe is studying from 1,334 Brukinsa users. Check the latest studies of Brukinsa.

What is Nasopharyngitis?

Nasopharyngitis (inflammation of the nasopharynx) is found to be associated with 2,433 drugs and 2,241 conditions by eHealthMe. Check the latest studies of Nasopharyngitis.

On Jul, 30, 2026

1,330 people reported to have side effects when taking Brukinsa.
Among them, 23 people (1.73%) have Nasopharyngitis.

Among these 23 people:

How long have people been on Brukinsa when they have Nasopharyngitis? *

What is the gender of people who have Nasopharyngitis when taking Brukinsa? *

female: 50 %
male: 50 %

What is the age of people who have Nasopharyngitis when taking Brukinsa? *

What are other drugs people take besides Brukinsa? *

Imbruvica: 4 people, 17.39%
Dupixent: 3 people, 13.04%
Venclexta: 3 people, 13.04%
Neulasta: 3 people, 13.04%
Neupogen: 3 people, 13.04%
Nifedipine: 2 people, 8.70%
Febuxostat: 2 people, 8.70%
Coenzyme Q10: 2 people, 8.70%
Methionine: 2 people, 8.70%
Moxifloxacin Hydrochloride: 2 people, 8.70%

What are other side effects people have besides Nasopharyngitis? *

Head Injury: 5 people, 21.74%
Haemoglobin Decreased: 5 people, 21.74%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 17.39%
Weakness: 4 people, 17.39%
Chest Pain: 4 people, 17.39%
Constipation: 4 people, 17.39%
White Blood Cell Count Decreased: 4 people, 17.39%
Thrombocytopenia (decrease of platelets in blood): 4 people, 17.39%
Drowsiness: 4 people, 17.39%
Febrile Neutropenia (fever with reduced white blood cells): 3 people, 13.04%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 8 people, 34.78%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 5 people, 21.74%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 3 people, 13.04%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 8.70%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 4.35%
Lymphoma (cancer that begins in immune system cells): 1 person, 4.35%
High Blood Pressure: 1 person, 4.35%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 4.35%
B-Cell Small Lymphocytic Lymphoma (blood cancer affecting b cells): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Brukinsa and have Nasopharyngitis?

- Check whether Nasopharyngitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Brukinsa:

Brukinsa (1,334 reports)

Nasopharyngitis treatments and more:

Nasopharyngitis (239,332 reports)

Browse all side effects of Brukinsa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nasopharyngitis:

Nasopharyngitis (2,433 drugs)

Browse all the conditions that are associated with Nasopharyngitis:

Nasopharyngitis (2,241 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zanubrutinib (the active ingredients of Brukinsa) and Brukinsa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.